Dr. Tripuraneni has served as our Chief Development Officer since 2018. Prior to that, she was our Vice President, Medical Affairs & Development Operations. Before joining Prothena, Dr. Tripuraneni was Vice President, Medical Affairs of MyoKardia Inc., a position she held from 2017 to 2018. From 2012 to 2017, she was Vice President, Medical Affairs at Synageva BioPharma Corp. and then Alexion Pharmaceuticals, which acquired Synageva in 2015. Dr. Tripuraneni held medical director positions at Gilead Sciences, Inc. and Genzyme Corporation, and prior to that worked at Summer Street Research Partners, a boutique equity research firm. Dr. Tripuraneni earned her BAs in business and liberal arts and her MD from the University of Missouri, and her Master’s in Public Health from Harvard University. She did her clinical training in general surgery at Harvard – Beth Israel Deaconess Medical Center.